It acts as a selective estrogen receptor modulator (SERM), similar to tamoxifen and raloxifene.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) nameb.

This makes the feedback receptors in the brain to receive Clomiphene instead of estrogen. Mechanism of action: The ovulatory response to cyclic Clomid 50 mg Tablets therapy is mediated through increased output of pituitary gonadotrophins, which in turn stimulates the maturation and endocrine activity of the ovarian follicle. Detailed Description: Clomiphene citrate has been widely used alone, and in combination with intrauterine insemination (IUI), for treatment of unexplained subfertility, The mechanism of action is based on its mixed estrogenic and antiestrogenic properties. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues. Used to induce ovulation in appropriately selected anovulatory women desiring pregnancy in whom ovulatory dysfunction has been demonstrated. Likelihood of conception decreases with each succeeding course of therapy.Available as clomiphene citrate; dosage expressed in terms of the salt.If ovulation occurs after initial course of therapy, continue with initial dosage of 50 mg once daily for 5 days starting on the fifth day of the menstrual cycle in subsequent treatment cycles.≥6 cycles of therapy (including 3 ovulatory cycles) not recommended.Maximum 6 cycles of therapy (including 3 ovulatory cycles); safety of long-term cyclic use not conclusively demonstrated.No special population dosage recommendations at this time.Ovarian cysts or enlargement (unless due to polycystic ovarian syndrome).Presence of an organic intracranial lesion (e.g., pituitary tumor).Known hypersensitivity to clomiphene or any ingredient in the formulation.May cause fetal harm; teratogenicity and fetotoxicity demonstrated in animals.Dose-related adverse ocular effects (i.e., blurring of vision, scotomata, electroretinographic changes in retinal function, phosphenes, diplopia, photophobia, decreased visual acuity) reported;Visual symptoms may result from intensification and prolongation of after-images and may be precipitated by a brightly lit environment.Discontinue therapy if visual symptoms occur; prompt ophthalmologic evaluation recommended.Risk of uncomplicated ovarian enlargement and cyst formation; may be accompanied by abdominal or pelvic pain, or distension.Monitor for signs and symptoms of excessive ovarian stimulation (e.g., pelvic pain).Risk of potentially severe OHSS; may progress rapidly and is initially manifested by abdominal pain and distension, nausea, vomiting, diarrhea, and weight gain.Transient liver function test abnormalities, which may be accompanied by morphologic changes (as detected by liver biopsy) have been reported.If ovaries are abnormally enlarged, discontinue therapy until ovaries return to pretreatment size; reduce dosage or duration of the next course of therapy.Increased retention of sulfobromophthalein has occurred.Potential for exaggerated response (e.g, ovarian hyperstimulation) to usual dosages of clomiphene in patients with polycystic ovary syndrome who are overly sensitive to gonadotropin.Risk of borderline or invasive ovarian tumors; may be associated with prolonged therapy.Prior to initiating therapy and each subsequent course of therapy, perform a thorough pelvic examination and rule out pregnancy, ovarian enlargement, or ovarian cyst.Prior to initiating therapy, evaluate for adequate endogenous estrogen levels (e.g., from vaginal smears, endometrial biopsy, urinary estrogen assay, and bleeding response to progesterone).Prior to initiating therapy, evaluate liver function.If abnormal vaginal bleeding is present, evaluate carefully to rule out neoplastic lesions.Perform endometrial biopsy prior to initiating therapy in women with increased risk of endometriosis or endometrial carcinoma (e.g., older women).Possible enlargement of existing uterine fibroids; use with caution in women with uterine fibroids.Risk of multiple ovulations with resulting plural gestations, including bilateral tubal pregnancy and coexisting tubal and intrauterine pregnancy;Not known whether clomiphene is distributed into milk.

With careful selection and proper management of the patient, clomiphene citrate has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy. We comply with the HONcode standard for trustworthy health information -

AHFS drug information 2007. Mechanism of action/Effect: Clomiphene has mainly antiestrogenic effects and some estrogenic effects {04} {10} {42} {52} {53} {54} {55} {57} {60} {61} {62} {73} {74} {80}. Available for Android and iOS devices. Estrogen agonist-antagonist; a nonsteroidal ovulatory stimulant.Used to induce ovulation in appropriately selected anovulatory women desiring pregnancy in whom ovulatory dysfunction has been demonstrated.Optimum results obtained in patients with adequately functioning anterior pituitary gland, adrenals, ovaries, and thyroid, including women with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of unknown etiology.Ineffective in patients with primary pituitary or ovarian failure;Manufacturer states that clomiphene is not recommended to induce ovulation associated with in vitro fertilization programs.Should be prescribed by clinicians experienced in management of gynecologic and endocrine disorders.Carefully evaluate patient prior to each course of therapy to exclude pregnancy, ovarian enlargement, or ovarian cyst formation.Prior to initiating therapy, carefully evaluate patient for adequate endogenous estrogen levels, for primary pituitary or ovarian failure, and for the presence of endometriosis, endometrial carcinoma, or uterine fibroids.Therapy may be started at any time in patients with no recent uterine bleeding.Majority of responding patients will ovulate after the first course of therapy, generally within 5–10 days.Prolonged amenorrhea may be less responsive and may require ≥2 cycles of therapy. Estrogen agonist-antagonist; a nonsteroidal ovulatory stimulant. It works by causing the release of GnRH by the hypothalamus, and subsequently gonadotropin from the anterior pituitary. McEvoy GK, ed. Mechanism of Action.

Mechanism of action: There is a lot of similarity between Clomiphene and estrogen in the structure. Clomifene was approved for medical use in the United States in 1967. a b Uses for Clomiphene Citrate Female Infertility. Clomiphene citrate is a drug of considerable pharmacologic potency. PHARMACOLOGY/MECHANISMS OF ACTION Clomiphene is a nonsteroidal triphenylethylene derivative distantly related to diethylstilbestrol.

https://www.webmd.com/drugs/2/drug-13979/clomiphene-citrate-oral/details